Oxcarbazepine or Eslicarbazepine Metabolite (MHD)
0098834
Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
Mnemonic
OXCARB
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-2 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
- Collect
- Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).
- Specimen Preparation
- Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
- Remarks
- Stability
- After separation from cells: Ambient: 6 weeks; Refrigerated: 6 weeks; Frozen: 3 months (avoid repeated freeze/thaw cycles)
Reference Interval
Effective November 18, 2013
Therapeutic Range: | 3-35 µg/mL |
Toxic: | Greater than 40 µg/mL |
Interpretive Data
This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia and tremor.
Note
Hotline History
View Hotline History
CPT Code(s)
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0098834 | Oxcarb or Eslicarb Metabolite (MHD) | 31019-3 |
Aliases
- 10-Hydroxy-10,11-Dihydrocarbamazepine
- 10-Hydroxycarbazepine
- 10-OH-Carbazepine (MHD)
- 11-Dihydrocarbamazepine
- Eslicarbazepine
- GP 47680
- Metabolite of Oxcarbazepine
- MHC
- MHD
- Monohydroxy Carbamazepine
- Monohydroxy Carbamazepine (MHD)
- Oxcarbazepine
- Oxcarbazepine Metabolite
- Oxcarbazepine Metabolite, 10-Hydroxy-10
- Trileptal (Parent Pro-Drug)